Brenda J. Boersma

Brenda J. Boersma

Auto-generated profile, based on publicly available information

Brenda J. Boersma

Laboratory of Human Carcinogenesis, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, Maryland (MD), USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Sharon GlynnSharon Glynn
Sharon Glynn
BBBrenda J. Boersma
Brenda J. Boersma
TDTiffany H. Dorsey
Tiffany H. Dorsey
MYMing Yi
Ming Yi
HYHarris G. Yfantis
Harris G. Yfantis
Stefan AmbsStefan Ambs
Stefan Ambs
Inducible nitric oxide synthase (NOS2) is involved in wound healing, angiogenesis, and carcinogenesis. NOS2 upregulation and increased nitric oxide (NO) production affect the redox state of cells and can induce protein, lipid, and DNA modifications. To investigate whether NOS2 levels influence survival of breast cancer patients, we examined NOS2 expression and its association with tumor markers and survival in 248 breast tumors. In multivariable survival analysis, increased NOS2 predicted inferior survival in women with estrogen receptor α–negative (ER-negative) tumors. Microdissected tumor epithelium from ER-negative tumors with high NOS2 had increased IL-8 and a gene expression signature characteristic of basal-like breast cancer with poor prognosis. In cell culture, NO only induced selected signature genes in ER-negative breast cancer cells. ER transgene expression in ER-negative cells inhibited NO-induced upregulation of the stem cell marker CD44 and other proteins encoded by signature genes, but not of IL-8. Exposure to NO also enhanced cell motility and invasion of ER-negative cells. Last, pathway analysis linked the tumor NOS2 gene signature to c-Myc activation. Thus, NOS2 is associated with a basal-like transcription pattern and poor survival of ER-negative patients.

19 February 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DMDamali N. Martin
Damali N. Martin
BBBrenda J. Boersma
Brenda J. Boersma
MYMing Yi
Ming Yi
MRMark Reimers
Mark Reimers
THTiffany M. Howe
Tiffany M. Howe
Stefan AmbsStefan Ambs
Stefan Ambs
African-American breast cancer patients experience higher mortality rates than European-American patients despite having a lower incidence of the disease. We tested the hypothesis that intrinsic differences in the tumor biology may contribute to this cancer health disparity. Using laser capture microdissection, we examined genome-wide mRNA expression specific to tumor epithelium and tumor stroma in 18 African-American and 17 European-American patients. Numerous genes were differentially expressed between these two patient groups and a two-gene signature in the tumor epithelium distinguished between them. To identify the biological processes in tumors that are different by race/ethnicity, Gene Ontology and disease association analyses were performed. Several biological processes were identified which may contribute to enhanced disease aggressiveness in African-American patients, including angiogenesis and chemotaxis. African-American tumors also contained a prominent interferon signature. The role of angiogenesis in the tumor biology of African-Americans was further investigated by examining the extent of vascularization and macrophage infiltration in an expanded set of 248 breast tumors. Immunohistochemistry revealed that microvessel density and macrophage infiltration is higher in tumors of African-Americans than in tumors of European-Americans. Lastly, using an in silico approach, we explored the potential of tailored treatment options for African-American patients based on their gene expression profile. This exploratory approach generated lists of therapeutics that may have specific antagonistic activity against tumors of African-American patients, e.g., sirolimus, resveratrol, and chlorpromazine in estrogen receptor-negative tumors. The gene expression profiles of breast tumors indicate that differences in tumor biology may exist between African-American and European-American patients beyond the knowledge of current markers. Notably, pathways related to tumor angiogenesis and chemotaxis could be functionally different in these two patient groups.

12 November 2007 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
BBBrenda J. Boersma
Brenda J. Boersma
MRMark Reimers
Mark Reimers
MYMing Yi
Ming Yi
JLJoseph A. Ludwig
Joseph A. Ludwig
BLBrian T. Luke
Brian T. Luke
Stefan AmbsStefan Ambs
Stefan Ambs

5 July 2006 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
BBBrenda J. Boersma
Brenda J. Boersma
THTiffany M. Howe
Tiffany M. Howe
JGJulie E. Goodman
Julie E. Goodman
HYHarry G. Yfantis
Harry G. Yfantis
DLDong H. Lee
Dong H. Lee
Stefan AmbsStefan Ambs
Stefan Ambs
Background: A common single-nucleotide polymorphism (SNP) in the promoter region of the MDM2 gene, known as T-309G and referred to as SNP309 for this study, leads to increased expression of Mdm2 protein and attenuated function of the p53 tumor suppressor protein. We investigated whether genetic variants in MDM2 were associated with breast cancer incidence and survival and whether the variant status could interact with the tumor p53 status to modify breast cancer survival. Methods: We used multivariable logistic and Cox regression analyses to study the relationship of SNP309 status and the status of a second MDM2 SNP in exon 12 at codon 354 (SNP354) with breast cancer incidence and with disease-specific survival among 293 case patients and 317 cancer-free control subjects. Survival analysis included 248 of the 293 case patients who had known tumor p53 status. All statistical tests were two-sided. Results: We did not observe an association between SNP309 status and breast cancer incidence in the unstratified analysis, but we did find a statistically significant association between SNP354 status and breast cancer incidence (odds ratio = 3.34, 95% confidence interval [CI] = 1.88 to 5.93). We also discovered a statistically significant interaction between SNP309 status and tumor p53 expression for breast cancer survival ( Pinteraction = .002). Among homozygous carriers of the common MDM2 SNP309 allele (T/T), a mutant p53 status (risk ratio [RR] of death = 2.33, 95% CI = 1.08 to 5.03) and aberrant p53 protein expression (RR = 2.61, 95% CI = 1.22 to 5.57) in breast tumors were associated with poor survival. Tumor p53 status was not associated with breast cancer survival among carriers of the variant MDM2 SNP309 allele (G/T or G/G), which is consistent with a dominant effect of the variant allele. Conclusion: A strong interaction between SNP309 status and tumor p53 status appears to modify the association between p53 status and breast cancer survival.

27 December 2006 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
RPRobyn L. Prueitt
Robyn L. Prueitt
BBBrenda J. Boersma
Brenda J. Boersma
THTiffany M. Howe
Tiffany M. Howe
JGJulie E. Goodman
Julie E. Goodman
DTDouglas D. Thomas
Douglas D. Thomas
Stefan AmbsStefan Ambs
Stefan Ambs
Akt signaling may promote breast cancer progression and poor disease outcome. We hypothesized that serum insulin‐like growth factor I (IGF‐I) and a proinflammatory tumor environment induce phosphorylation of Akt and downstream targets of Akt in breast cancer. We studied the relationship between Akt pathway activation, IGF‐I and markers of inflammation, e.g., nitric oxide synthase‐2 (NOS2), cyclooxygenase‐2 (COX2) and tumor phagocyte density, in 248 breast tumors. We also examined the association of Akt phosphorylation with breast cancer survival. We observed that phosphorylation of Akt, BAD and caspase‐9 correlated strongly with the expression of the 2 proinflammatory enzymes, NOS2 and COX2, in breast tumors (p < 0.001; Spearman rank correlation). Both NOS2 and COX2 expression were independently associated with Akt phosphorylation in the multivariate analysis. Serum IGF‐I concentrations and the IGF‐I/IGFBP3 ratio correlated with Akt phosphorylation at Thr308 and Ser473 in breast tumors (p ≤ 0.05; Spearman rank correlation). The association with Akt phosphorylation at Thr308 remained statistically significant in the multivariate analysis. Akt pathway activation was not associated with overall survival in the unstratified analysis, but we observed a statistical interaction between Akt phosphorylation and tumor phagocyte density on breast cancer survival (pinteraction < 0.05). We further corroborated our findings in cell culture models by demonstrating that ANA‐1 macrophages, nitric oxide and prostaglandin E2 induce Akt phosphorylation in human breast cancer cells. In summary, a proinflammatory environment was found to activate the Akt pathway in breast cancer, and may modify the association between the Akt phosphorylation status and breast cancer survival.

30 November 2007 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
NCNigel P. S Crawford
Nigel P. S Crawford
XQXiaolan Qian
Xiaolan Qian
AZArgyrios Ziogas
Argyrios Ziogas
APAlex G Papageorge
Alex G Papageorge
BBBrenda J Boersma
Brenda J Boersma
KHKent W Hunter
Kent W Hunter
A novel candidate metastasis modifier, ribosomal RNA processing 1 homolog B (Rrp1b), was identified through two independent approaches. First, yeast two-hybrid, immunoprecipitation, and functional assays demonstrated a physical and functional interaction between Rrp1b and the previous identified metastasis modifier Sipa1. In parallel, using mouse and human metastasis gene expression data it was observed that extracellular matrix (ECM) genes are common components of metastasis predictive signatures, suggesting that ECM genes are either important markers or causal factors in metastasis. To investigate the relationship between ECM genes and poor prognosis in breast cancer, expression quantitative trait locus analysis of polyoma middle-T transgene-induced mammary tumor was performed. ECM gene expression was found to be consistently associated with Rrp1b expression. In vitro expression of Rrp1b significantly altered ECM gene expression, tumor growth, and dissemination in metastasis assays. Furthermore, a gene signature induced by ectopic expression of Rrp1b in tumor cells predicted survival in a human breast cancer gene expression dataset. Finally, constitutional polymorphism within RRP1B was found to be significantly associated with tumor progression in two independent breast cancer cohorts. These data suggest that RRP1B may be a novel susceptibility gene for breast cancer progression and metastasis. Metastasis, which is defined as the spread of malignant tumor cells from their original site to other parts of the body, accounts for the vast majority of solid cancer-related mortality. Our laboratory has previously shown that host germline-encoded variation modifies primary tumor metastatic capacity. Here, we detail how germline-encoded Rrp1b variation likely modulates metastasis. In mice, constitutional Rrp1b variation correlates with ECM gene expression, which are genes commonly differentially regulated in metastasis prone tumors. Furthermore, we demonstrate that Rrp1b expression levels are modulated by germline variation in mice with differing metastatic propensities, and that variation of Rrp1b expression in a highly metastatic mouse mammary tumor cell line modifies progression. Differential RRP1B functionality also appears to play an important role in human breast cancer progression. Specifically, we demonstrate that a microarray gene expression signature indicative of differential RRP1B expression predicts breast cancer-specific survival. Furthermore, we show that germline-encoded RRP1B variation is associated with markers of outcome in two breast cancer populations. In summary, these data suggest that Rrp1b may be a germline-encoded metastasis modifier in both mice and humans, which leads to the possibility that knowledge of RRP1B functionality and variation in breast cancer might facilitate improved assessment of prognosis.